RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Bellen Chemistry, a Beijing CRO/CMO, raised “hundreds of millions in RMB” ($30 million plus) in a C financing round. The company offers chemical synthesis for chemical drugs based on its large library of heterocycles. Founded in 2007, Bellen has its headquarters and a research lab in Beijing, a research center in Shanghai, and a manufacturing base in Shandong province. The round was led by Apricot Capital, CMB and Qianhai Fund of Funds. One year ago, Bellen completed a $38 million B financing intended mainly for its manufacturing operations.
Source: China Biotoday
